MedTrace Logo

DUR-928 in Subjects With SARS-CoV-2 With Acute Lung, Liver or Kidney Injury

NCT04447404 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2022-08-05

Study results available
· View outcomes & findings →

Summary

Evaluate safety and efficacy of DUR-928 in treatment of acute organ failure in subjects infected with SARS-CoV-2

Conditions

Interventions

DRUG

DUR-928

IV infusion

DRUG

Placebo

IV infusion

Sponsors & Collaborators

  • Durect

    lead INDUSTRY

Principal Investigators

  • Robert Gordon, MD · CTI Clinical Trial and Consulting Services

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-21
Primary Completion
2021-03-04
Completion
2021-03-04
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04447404 on ClinicalTrials.gov